A study of a new drug for certain cancers with a specific gene change
Treatments studied
Part of Cancer clinical trials.
This trial tests a drug called telisotuzumab adizutecan for people whose cancer has a specific genetic change called MET amplification. It may help when standard treatments are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a solid tumor cancer that has spread or cannot be removed with surgery.
- Your cancer must have a specific gene change called MET amplification, confirmed by a genetic test.
- You must be able to take care of yourself (ECOG score 0 or 1).
- Your tumor must be measurable on scans like CT or MRI.
- You must have already tried at least one standard treatment for your cancer type.
- If cancer has spread to the brain, it must be stable or not causing symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for people with metastatic colorectal cancer. The study includes an experimental antibody-drug conjugate (telisotuzumab adizutecan) plus standard chemotherapy and targeted therapies, to see if it works better than current options.
This trial tests a new drug (ANS014004) for people with advanced solid tumors that have a specific gene change (MET, ROS1, or NTRK). It aims to see if the drug is safe and can shrink tumors.
This trial tests a new combination of two drugs (telisotuzumab adizutecan and pembrolizumab) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination can help control the cancer and to find the best dose.
This trial tests a new combination treatment for people with advanced non-squamous non-small cell lung cancer who haven't received prior therapy for advanced disease and don't have specific gene changes. The treatment includes an antibody-drug conjugate (telisotuzumab adizutecan) plus an immunotherapy drug (PD-1 checkpoint inhibitor) to see if it helps shrink tumors and improve outcomes.
This trial tests a new drug, telisotuzumab adizutecan (given through a vein), alone or with another targeted therapy, versus standard treatments for people with a specific type of advanced lung cancer that has an EGFR mutation and has gotten worse after previous treatment.
This study tests a new drug called telisotuzumab adizutecan against the usual treatments for people with a type of lung cancer that has spread and has not responded to previous therapy. It may be an option if your cancer has a specific marker and you have not had certain other conditions.
Hear when a new Solid Tumors Harboring MET Amplification trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.